The FDA wants to give biotech drugs more distinct names, but some drugmakers and agencies aren't on board.
An FDA plan to give biotech drugs more distinct names is facing criticism from multiple sides, including some drugmakers and the federal agency in charge of competition.
At issue is guidance that calls for the addition of different suffixes to the names of original brand name biologics — complex drugs made from living materials — and their copies, called biosimilars.
